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Abstract
The National Cancer Research Institute (NCRI) is a partnership of charity and government research funders whose 
purpose is to improve health and quality of life by accelerating progress in cancer-related research through col-
laboration. Under this umbrella, the NCRI Brain Tumor Clinical Studies Group is focused on improving clinical 
outcomes for adult patients with brain and central nervous system tumors, including those with brain metastasis 
from other primary sites. This document discusses the current state of clinical brain tumor research in the United 
Kingdom and the challenges to increasing study and trial opportunities for patients. The clinical research priorities 
are defined along with a strategy to strengthen the existing brain tumor research network, improve access to tissue 
and imaging and to develop the future leadership for brain tumor research in the United Kingdom. This strategy 
document may serve as a framework for other organizations and countries.
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The National Cancer Research Institute (NCRI) partnership 
was established in 2001 to ensure collaboration and coor-
dination amongst cancer research funders in order to max-
imize the value and benefits of cancer research for patients 
and the public. Within the NCRI, clinical studies groups 
(CSGs) were established across the major cancer sites 
to provide a forum for stakeholders to develop trials and 
build a strategic portfolio within their areas of expertise. 
The original remit of the CSGs was to promote trials within 
the clinical community and also to provide constructive 
support for study proposals prior to submission to funding 
agencies. More recently the remit has changed and CSGs 
are now expected to be more active in developing clinical 
trials in-house, with particular emphasis on interventional 
rather than observational studies.
Since its formation, the brain tumor CSG has been sup-
ported by subgroups; namely (i) Translational and Novel 
Agents, (ii) Imaging and Technology (originally separate 
groups which merged in 2012), and (iii) Supportive and 
Palliative Care. These subgroups provided a crosscutting 
approach to studies across all brain tumor types. Pediatric 
brain tumors fall under the remit of the Children’s Cancer 
and Leukaemia CSG and due to the age eligibility criteria 
for most clinical trials, the groups function largely inde-
pendently. Over the last decade the number of trials on 
the NCRI portfolio has increased. Neurosurgeons have 
developed and led both surgical trials such as GALA-51 
and GALA-BIDD2 and radiotherapy trials such as the ROAM 
trial (an international, multicenter, phase III trial for atypical 
meningioma).3 Imaging trials such as DIG PRaM-GBM have 
been developed and led by neuroradiologists and neuro-
surgeons. Similar success has been achieved by oncolo-
gists who have taken laboratory research in DNA damage 
and repair biology into clinical trials for patients with glio-
mas, in the form of the PARADIGM4 and OPARATIC trials.5
Despite these successes, feedback from the NCRI high-
lighted that by their nature only a limited number of 
patients were eligible for these trials. Targeting therapeu-
tics in stratified patient cohorts is likely to exacerbate this 
trend, and such trends are exacerbated in less common 
cancers such as those of the brain. There is a need to bal-
ance how we can achieve large-scale research involving 
patients across the whole of the United Kingdom (UK) and 
addressing all aspects of the cancer journey.
The NCRI brain tumor CSG held a strategy meeting at 
Peterhouse College, Cambridge on October 10-11, 2016. 
Members of the CSG and subgroups, along with repre-
sentatives from The Brain Tumor Charity, brainstrust—
the brain cancer people, Cancer Research UK (CRUK), 
the Department of Health, and the National Institute of 
Health Research discussed the current state of brain tumor 
research in the UK and its future challenges. This document 
summarizes those discussions and outlines a forward 
strategy for clinical brain tumor research in the UK.
Burden of Disease
Approximately 9000 patients are diagnosed with a primary 
brain tumor each year in the UK, and it has been estimated 
that 16,000 patients suffer from brain metastasis from 
other primary sites, making a total of approximately 25,000 
patients affected per year in the UK.6 Over 102,000 people 
are living with a brain tumor in the UK7 and, overall, only 
14% of patients with primary brain cancer are alive 10 years 
after diagnosis.6 Although there are approximately 120 dif-
ferent types of brain tumor, the most common are gliomas, 
meningiomas, and metastases from extracranial sites such 
as breast, lung, kidney, and skin. Glioblastoma is the most 
common primary malignant brain tumor and the cause of 
the greatest average loss of life-years among all cancers,8 
with a 2-year survival of approximately 25% and 5-year 
survival of approximately 5%.9
Meningiomas, meanwhile, are the most common pri-
mary intracranial tumor overall. The majority can be 
cured by surgical resection but in a subset of patients 
with clinically aggressive meningioma the tumor may 
recur. Radiotherapy may also help control these tumors, 
but there are no effective chemotherapy treatments.10 
Furthermore, cure or disease control does not necessarily 
equate to maintained quality of life and patients can often 
suffer a great deal of morbidity due to the location of the 
meningioma and the post-treatment effects.
Brain metastases affect up to 40%11 of patients with an 
extracranial primary cancer, with an increasing incidence 
because of both more effective control of the primary 
tumor and greater use of brain imaging for detection 
of metastasis. Surgery, stereotactic radiosurgery, and 
whole-brain radiotherapy continue to be the mainstay of 
treatment, but increasingly therapies are targeted accord-
ing to primary tumor type, including molecular subtype. 
Although some patients undoubtedly benefit from these 
targeted therapies, the overall prognosis for brain metas-
tases is generally poor, and there are few effective treat-
ments that can achieve long-term control.11,12
Although the incidence, care pathways, and specialists 
involved vary according to primary and secondary brain 
tumors, all types have a major impact on patients and car-
ers, since they directly affect personality, mood, speech, 
physical function, cognitive function, seizure threshold, 
and levels of fatigue. As such, common themes emerge 
regardless of tumor type; for example, the primary effect 
of the tumor and the destructive or toxic side effects of 
the treatment (surgery, radiotherapy, and chemotherapy). 
Accordingly, quality of life is a major issue for patients liv-
ing with and beyond brain cancer. Taken together there is 
an urgent need both to improve brain tumor survival and 
to improve the quality of life for those who do live longer 
and have additional morbidity from treatment.
Stakeholders in Brain Tumor Research
Patients with brain tumors can suffer from a range of 
neurological and quality-of-life issues that require coor-
dinated management by a large multidisciplinary team. 
NICE Guidance on “improving outcomes for people with 
brain and other CNS tumors” (https://www.nice.org.uk/
guidance/csg10) identifies key multidisciplinary team 
members, including neurosurgeons, neurologists, neuro-
pathologists, neuroradiologists, oncologists, clinical nurse 
specialists, and allied health professionals. Many different 
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professions and organizations therefore contribute to and 
are integral to brain tumor research. There is strong back-
ing within this community to fund and support research 
that will directly benefit patients, families, and carers. 
As well as Cancer Research UK (CRUK), charities specifi-
cally dedicated to brain cancer research include The Brain 
Tumour Charity, Brain Tumour Research, and brainstrust—
the brain cancer people. These charities have their own 
unique approach to brain cancer research—for example, 
brainstrust is a patient-facing support charity and focuses 
on clinical research to improve patient and caregiver qual-
ity of life. The Brain Tumor Research charity is very active 
at lobbying for additional government funding as well as 
fundraising for several Brain Tumour Research Centres 
of Excellence at universities in the UK. The Brain Tumour 
Charity raises money to fund research through program 
and project grants. Despite these differences they all iden-
tify brain cancer as a priority area and nurturing this broad 
community of stakeholders is central to improving out-
comes for patients living with brain tumors.
Funding Landscape: Lessons From Other 
Cancers
Two types of cancer demonstrate clearly the positive long-
term correlation between research investment and survival 
rates; namely breast cancer and leukemia, which account 
for 8.5% and 6.9% of all NCRI spending, respectively 
(https://www.ncri.org.uk). Breast cancer survival after 
5 years is now as high as 84.3%, despite more than 50,000 
new cases being diagnosed every year. This remarkable 
success story is the product of sustained funding over 
decades, helping inform a detailed understanding of 
underlying tumor biology that in turn translates into new 
treatments.
Brain tumor research is not at this advanced stage of 
investment or understanding and the cumulative research-
spend on brain tumors in the UK between 2002 and 2011 
was less than 1%, and in 2014 only 1.5% of all research-
spend by the NCRI (https://www.ncri.org.uk). The rarity of 
brain tumor compared to breast cancer and leukaemia is 
no doubt a factor that contributes to the lower levels of 
funding. Compounding this underfunding, brain tumors 
benefit very little from advances elsewhere in “general 
cancer research” since brain tumors are very different 
from other cancers. In particular the blood-brain barrier 
makes it more difficult for novel treatments, developed for 
systemic cancers, to reach the tumor at therapeutic con-
centrations. Encouragingly, brain tumors have been identi-
fied as a cancer of unmet need and prioritized for research 
funding, such that CRUK would like to see a 2- to 3-fold 
increase in spend over the next 5 years.13 While increased 
investment in research does not come with guarantees of 
lowering mortality, the more we understand these com-
plex cancers and invest in research infrastructure, the 
greater chances we will have to treat them effectively over 
the ensuing decades, adding both years to life and life to 
years of the affected patients and their families. In addi-
tion it is essential to engage with initiatives to promote 
international collaborative working that can usefully pool 
resources and expertise—especially for the rarer subtypes 
of brain tumors. Examples include the International Rare 
Cancers Initiative14 and the European rare cancer network 
EUROCAN.15
Brain Tumor Research Priorities
A key part of developing a strategy is having a shared 
perspective on the priorities for research. The James Lind 
Alliance (JLA) is funded through the National Institute 
of Health Research and aims to address uncertainties 
about the effects of treatment. It achieves this by bring-
ing together patients, carers, and clinicians to agree which 
clinical areas matter most and deserve priority attention. In 
2015, the JLA Neuro-Oncology Priority Setting Partnership 
identified 10 clinical areas in brain and spinal cord tumors 
on which the research community should focus (Table 1).16 
They cover all aspects of the patient journey, including 
lifestyle factors, early diagnosis, surgery, radiotherapy, 
disease monitoring, molecular genetics, imaging, quality 
of life, and symptom burden. Most of the JLA priorities 
are focused on primary brain tumors; however, some also 
map onto brain metastases. Many of these map onto NHS 
service provision and clinical studies, which fall within the 
remit of the brain CSG. The JLA top 10 priority questions 
provide a valuable benchmark and a useful framework for 
developing a research strategy, however the development 
of new clinical studies should not be restricted to these pri-
orities alone. Nevertheless, the clinical importance of these 
research priorities are exemplified as follows.
JLA Priority 3: Early Diagnosis of Brain Tumors
Symptoms of a developing brain tumor can be nonspe-
cific, and the average general practitioner will see few 
patients who are diagnosed with a brain tumor during 
the course of their career. In the UK in 2013, 38% of brain 
tumor patients visited their general practitioner more than 
5 times before diagnosis.17 Indeed 62% of all brain cancers 
are only discovered following presentations via accident 
and emergency departments, even when the same patient 
often previously presented to their general practitioner. 
This delay in diagnosis increases patient anxiety, and may 
impact on treatment options and outcome. Timely diagno-
sis of brain tumors remains a challenge. The ambition is 
that earlier diagnosis will identify tumors at a smaller size, 
which might be more amenable to complete surgical resec-
tion, in turn leading to a better outcome and prognosis.18
JLA Priority 6: Molecular Subtyping of Tumors
The advent of The Cancer Genome Atlas (TCGA) heralded a 
revolution in our molecular understanding of brain tumors. 
In May 2016 the World Health Organization (WHO) pub-
lished a revision of the 2007 classification of brain tumors19 
advising an integrated diagnosis combining molecular and 
genetic information of tumors with morphology in the clas-
sification process.20 A precise molecular diagnosis impacts 
on both research and routine clinical decision making, 
facilitating clinical and translational research by allowing 
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better stratification of patients based on the underlying 
biology of an individual’s tumor. It is envisaged this will 
facilitate the recruitment of more homogenous popula-
tions into clinical trials and support a pharmacogenomics 
exploration of datasets to create novel drug repositioning 
opportunities. Genome-wide screening at tumor progres-
sion/recurrence on tissue or liquid biopsies could facilitate 
patient reallocation in basket trials. However, at the inter-
face of research and clinical service delivery, one of the 
challenges is getting the appropriate test results within a 
clinically meaningful timeframe.
Challenges to Addressing the Research Priorities
The brain tumor research community in the UK is small. 
There are very few research-leading oncologists, neurora-
diologists, and neurologists, and only a modest number 
of brain tumor researchers in neurosurgery and neuropa-
thology. This has an impact on the breadth of leadership 
within the field, the ability to provide mentorship to aspir-
ing researchers and also the number of clinical studies that 
can be developed and delivered on to the NCRI portfolio for 
patients to access. Despite these challenges, in the UK all 
patients are treated within the NHS with good contribution 
to national clinical datasets, such as HES (Hospital Episode 
Statistics) and the various national cancer registries.
The current infrastructure to develop a clinical study 
relies heavily on individual university academics or 
research-active NHS clinicians to develop a research ques-
tion into a short proposal for review by the CSG and rel-
evant subgroups. That individual will make use of their 
local network of collaborators that may include a clinical 
trials unit lacking experience of brain tumor trials. This 
model is fundamentally flawed and relies heavily on a 
single motivated individual to navigate the complexities 
and nuances of grant applications, clinical trial develop-
ment, and protocol writing. Failure is more often because 
of limited experience with the process, time pressures, or 
limited supportive infrastructure, rather than the lack of a 
good idea.
In contrast, the pharmaceutical industry and European 
Organization for Research and Treatment of Cancer 
(EORTC) have access to infrastructure and expertise, but 
their trials will often only open in the UK in a few prese-
lected centers—typically the same 5 or 6 units for each 
successive trial. This inevitably leads to geographic vari-
ation in access to new trial drugs for patients. In addition, 
the pharmaceutical industry does not prioritize brain can-
cer for new drug development, due to the challenges of 
delivering trials in this small but diverse group of patients 
and the issue of drug delivery across the blood-brain bar-
rier. The research community persists in this approach 
in order to access novel agents and derive marginal but 
meaningful gains in prognosis and outcome, but it is wor-
thy to note that within the UK, medical oncologists, who 
tend to have dedicated research time and with whom 
the pharmaceutical industry often have most links, have 
not routinely been involved in brain tumor patient man-
agement. This stems from the UK’s dual training of clini-
cal oncologists in both systemic and radiation therapy 
and from the historical lack of effective systemic agents. 
However, with a growing focus on tailored, individualized 
therapy in all cancer groups, the lack of medical oncology 
involvement risks missing opportunities and cross-cutting 
expertise which might present themselves via early phase 
units and other connections. It is of note that most of the 
recent phase III trials in gliomas, while negative in terms of 
improving survival, have been from industry or the EORTC 
and the lead investigator has been a medical oncologist or 
neurologist.21–23
Table 1 James Lind Alliance Neuro-Oncology priority questions for research
Research Priority
1 Do lifestyle factors (e.g. sleep, stress, diet) influence tumour growth in people with a brain or spinal cord tumour?
2 What is the effect on prognosis of interval scanning to detect tumour recurrence, compared with scanning on symptomatic 
recurrence, in people with a brain tumour?
3 Does earlier diagnosis improve outcomes, compared to standard diagnosis times, in people with a brain or spinal cord 
tumour?
4 In second recurrence glioblastoma, what is the effect of further treatment on survival and quality of life, compared with best 
supportive care?
5 Does earlier referral to specialist palliative care services at diagnosis improve quality of life and survival in people with a  
brain or spinal cord tumours?
6 Do molecular subtyping techniques improve treatment selection, prediction and prognostication in people with a brain or  
spinal cord tumour?
7 What are the long-term physical and cognitive effects of surgery and/or radiotherapy when treating people with a brain or 
spinal cord tumour?
8 What is the effect of interventions to help carers cope with changes that occur in people with a brain or spinal cord tumour, 
compared with standard care?
9 What is the effect of additional strategies for managing fatigue, compared with standard care, in people with a brain or 
spinal cord tumour?
10 What is the effect of extent of resection on survival in people with a suspected glioma of the brain or spinal cord?
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A Strategy for Brain Tumor Research in 
the UK
The UK neuro-oncology research community is striv-
ing towards the dual goals of prevention or cure of brain 
tumors, and also that people living with and beyond a 
brain tumor should have the best quality of life possible. 
At present neither of these ambitions are remotely met. 
A strategy is needed that can encompass and harness the 
potential of the community as it works towards improving 
the diagnosis, treatment, prognosis, and supportive care 
of patients with brain tumors.
Strengthen the Existing Brain Tumor Research 
Network
Following publication of the “Neuro-Oncology JLA Top 
Ten” (Table  1), the stakeholders and funders involved 
in that process developed a strategy to improve the suc-
cess of funding applications for clinical research and 
clinical trials. This strategy includes collaborative multi-
center research, the support of Clinical Trials Units and 
the National Institute of Health Research Research Design 
Service, and early involvement of public and patient 
involvement through the use of focused “Incubator Days” 
(http://www.neuro-oncology.org.uk). Over the last 1 to 
2 years Incubator Days have been held to develop clinical 
trials to address epilepsy in glioma and the use of diet in 
glioma treatment. As a result, the existing network of clini-
cal researchers has been expanded and an application has 
been submitted to National Institute of Health Research for 
the SPRING trial (Seizure PRophylaxis IN Glioma). While 
this networked approach is more likely to generate suc-
cessful clinical trials grant applications, it relies heavily 
on existing networks and collaborators. The neurosurgical 
community has established a tumor section of the Society 
of British Neurological Surgeons to promote research 
that will enable early career surgeons to develop their 
ideas. A similar network, the British Neurosurgical Trainee 
Research Collaborative, exists for trainees to develop their 
ideas with established links to academic neurosurgeons 
across the UK and is successfully running a study on long-
term survivors with glioblastoma. In a similar fashion, the 
annual Glioma Club meeting provides a forum to foster 
interactions and networking between scientists and clini-
cians in the field.
Although the British Neuro-Oncology Society hosts an 
annual conference to provides a forum for scientists to 
interact with clinicians treating brain tumor patients, it is 
poorly attended by clinical oncologists or pediatric oncolo-
gists—for whom brain tumors may account for only a pro-
portion of their overall clinical practice. As such, clinical 
and pediatric oncologists are more likely to attend either 
more general cancer conferences or conferences targeted 
towards pediatric malignancies, respectively, for research 
updates. This has inevitably resulted in a poor network. 
However, in September 2016, Addenbrooke’s Hospital 
hosted a 2-day “bootcamp” that brought together clinical 
oncologists treating brain tumor patients from across the 
UK. A  follow-up “CNS bootcamp” is planned for 2017 to 
develop new clinical trials.
Improve Access to Tissue and Imaging
The limited impact of brain cancer research worldwide 
on clinical outcomes for patients is multifactorial. Central 
among these factors is a fundamental lack of understand-
ing of brain cancer biology. Rectifying this requires more 
dedicated research focused on brain tumors. A key priority, 
then, must be to invest more in fundamental research that 
will generate novel, rational therapies based on a clearer 
understanding of the biology of these tumors. This idea is 
gaining momentum in the UK but it will take many years 
for the clinical benefit to be realized. Parallel investment in 
translational research and infrastructure is equally impor-
tant to optimize the use of currently available drugs and 
technologies and to accelerate innovation into the clinic. 
Recent research has identified specific molecular biomark-
ers for brain cancer and research is urgently required to 
optimize their use to guide clinical management in the 
NHS. Imaging advances in humans and preclinical mod-
els can augment early phase drug development through 
mechanistic studies linked to tissue-derived data and 
measurement of novel agent distribution and CNS pen-
etration in vivo, in addition to providing early markers of 
therapeutic response in both early and later phase studies. 
Whilst the 100,000 Genomes Project will provide further 
insight into improving diagnosis, prognosis, and personal-
ized treatment of glioma,24 the real cornerstone to improv-
ing the understanding of brain tumor biology is to enable 
access to fully annotated tissue samples enriched with clin-
ical, imaging and outcome data.
Brain tumor biobank
Although biobanking is routine for most pediatric brain 
tumors, only around 30% of adult patients are asked about 
gifting tumor tissue for research and patients are often not 
aware that tissue surplus to diagnostic requirements could 
be used for future research. Health care professionals 
meanwhile are uncertain about the best time and method 
to broach the subject of tissue donation, and often the dis-
cussion does not take place.7 Furthermore, there is wide 
variation across the UK in the resources allocated for tis-
sue biobanking. BRAIN UK25 is a network of pathology lab-
oratories and 28 of 29 UK neuroscience centers have made 
their diagnostic and autopsy archives available to research-
ers. Nevertheless, more funding is needed to improve adult 
biobanking infrastructure to include frozen tissue samples, 
primary patient-derived tumor cells, and liquid biopsies to 
create an essential resource to support leading research 
into disease biology that will have an impact on treatment 
and care. Crucially, the biological material and molecular 
annotation must be supplemented with verified clinical 
data on symptoms, treatments, and outcomes. Investment 
is needed to develop the data infrastructure and regulatory 
framework that will allow this to happen on a routine basis. 
In tandem, a standard minimum imaging protocol should 
be developed and implemented so that every patient in 
every unit has the same MRI acquisition.
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A national biobank initiative is being developed to pro-
vide these valuable resources for laboratory and transla-
tional researchers. Support is essential to maximize sample 
collection by neurosurgeons (eg, technician support in the 
operating room) as well as cataloging in the neuropathol-
ogy department. The full complement of tissue, imaging, 
and clinical data is invaluable to researchers, and access to 
samples will be based purely on the scientific quality of the 
application and the proposed exit strategy of the research, 
as assessed by external peer reviewers—so-called scien-
tific meritocracy.
Developing Capacity
The UK clinical brain tumor research community must 
develop capacity in order to more-effectively deliver 
clinical studies, through investment in both people and 
infrastructure. There should be a move away from the tra-
ditional split of University “academics” and NHS (non-aca-
demic) clinicians, and instead to focus on clinical research 
teams that can effectively deliver successful grant applica-
tions and clinical trials.
People and infrastructure
The multidisciplinary nature of the management of brain 
tumors mandates that wider engagement of the clinical 
neuro-oncology community is essential in order to iden-
tify future sustainable leadership. More needs to be done 
to develop specialist clinical training in the UK through 
engagement with the Royal Colleges and specialist organi-
zations. Positive examples are the development of sub-
specialist neurosurgical oncology by the Society of British 
Neurological Surgeons and the Association of British 
Neurologists Neuro-Oncology Advisory Group. Within 
neuropathology, training in molecular pathology is to be 
implemented in the postgraduate curriculum—a positive 
step towards integrating molecular genetics into routine 
NHS practice, and a byproduct of which is likely to be 
research-active individuals. Clinical neuro-oncology imag-
ing forms part of the Royal College of Radiologists core 
curriculum for higher specialist/neuroradiology training, 
although exposure to advanced quantitative imaging tech-
niques is inconsistent across neuroscience centers. The 
latter is being addressed through training days recently 
instituted through the British Society of Neuroradiologists, 
however small numbers of trainees undertaking higher 
degrees towards clinical academic careers and clinical 
pressures in NHS posts limits research activity in imaging.
Dedicated fellowships for senior trainees that provide a 
broad exposure to both oncology and neurology could be 
considered. Efforts to promote neuro-oncology as a posi-
tive career for both clinical and medical oncology need to 
be developed and greater engagement by neurologists 
should be promoted. Indeed many of the functional con-
sequences of brain cancer and its treatment highlighted by 
patients are neurological (eg, seizures, fatigue, language 
disturbance, and cognitive changes) and more neurologists 
with an interest in brain cancer are required. Education in 
clinical trial development and implementation, through fel-
lowships or a higher degree, will help ensure that future 
neuro-oncology leaders will have the skills, contacts, and 
networks to deliver well-designed clinical trials.
A further point to consider is that in most other devel-
oped countries, once they have completed surgery and 
radiotherapy, adult brain cancer patients are managed 
by medical oncologists and neurologists. Brain cancer is 
a fundamental component of pediatric oncology training, 
but is not currently part of medical oncology training, but 
medical oncologists could deliver future drug trials as part 
of a wider research community. Indeed early phase trials 
in neuro-oncology are especially challenging and greater 
investment is required to develop a core number of units 
able to support brain cancer research with expertise on 
novel trial designs, in tandem with developing a cadre of 
research-leading clinical and medical oncologists.
Recruiting patients with brain cancer into clinical studies 
can be challenging therefore no single center will be able 
to deliver a suitably powered clinical trial. Several clinical 
trials units have experience in coordinating and deliver-
ing large multicenter brain cancer studies (eg, University 
of Liverpool, University of Glasgow, and University 
College London) and this network should be exploited and 
extended for future trials from the initial trial concept. The 
expertise provided in trial methodology and health eco-
nomics is invaluable for submitting competitive grants and 
ultimately delivering trials for patients into the research 
portfolio.
The Role of the Brain Tumor CSG
The NCRI Brain Tumor CSG overarching strategic aim is to 
support adult brain tumor research through outreach and 
stakeholder engagement, promoting capacity develop-
ment and training, developing data and tissue collection, 
and prioritizing clinical research throughout the patient 
journey. To implement the strategy the following are 
proposed:
•  Reorganization of the brain CSG subgroups: (i) the 
Glioma subgroup, (ii) the Meningioma, Metastases 
and other tumors subgroup, and (iii) the Survivorship 
subgroup. Changing the subgroup focus will facilitate a 
more disease-orientated approach and establish a clear 
framework for clinicians and researchers to discuss and 
develop their study and trial ideas
•  Complete a scoping exercise of clinical, imaging, and 
laboratory research interests across the UK to identify 
strengths, weaknesses, and existing collaborations with 
a view to strengthening the existing networks
•  Build the profile of the group through regular engage-
ment with the neuro-oncology community using exist-
ing networks. These networks include the Association of 
British Neurologists and Society of British Neurological 
Surgeons academic networks and newly formed 
tumor section; British Neurosurgical Trainees Research 
Collaborative; British Neuropathology Society; British 
Society of Neuroradiologists; CNS Bootcamp; Glioma 
Club; British Neuro-Oncology Society; BRAIN UK; and 
annual conference meetings
•  Through engagement activities, provide mentorship 
Downloaded from https://academic.oup.com/nop/article-abstract/doi/10.1093/nop/npx022/4098339/Brain-tumor-research-in-the-United-Kingdom-current
by Michael Jenkinson
on 04 September 2017
7Kurian et al. UK brain tumor research strategy
N
eu
ro-
O
n
colog
y
N
eu
ro-O
n
colog
y 
P
ractice
to early career clinicians with study ideas that can be 
developed via the CSG subgroups and encourage indi-
viduals to join the subgroups, which will aid with suc-
cession planning when members reach their term on the 
main group
•  Map the CSG strategy to the forthcoming CRUK strate-
gic review for brain tumor research key priorities
•  Ensure that the quality of research applications are 
internationally competitive prior to submission to fund-
ing organizations
Conclusions
Brain tumor research in the UK has increased over the last 
10 to 15  years, but a formal, cohesive national strategic 
direction has been lacking. In order to realize improvements 
in treatment and prognosis for patients with brain tumors 
we need to work collaboratively. Being a comparatively 
small academic community can be an advantage, and we 
should exploit this. Greater emphasis needs to be placed 
on co-leadership of research initiatives by a scientist and 
a clinician working together. This would allow scientists 
to optimize benefit from material and data generated in 
clinical studies and allow clinicians to ensure NHS practice 
is conducted in a research-supportive manner. National 
biobanking initiatives are essential to provide high-quality 
clinically, annotated samples, linked to national cancer reg-
istries that will drive translational research for new drug 
discovery. Finally we must identify those future leaders, 
both clinical and laboratory-based, who can build on the 
proposed strategy and further develop international col-
laborative research networks.
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